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Materials and Methods: Enrollees received Cb AUC 6 day 1 in 
combination with Pac 100 mg/m2 days 1, 8, and 15 every 4 weeks, and 
C225 at a loading dose of 400 mg/m2 day 1, then 250 mg/m2 weekly 
thereafter. C225 was continued as a single agent after 6 full cycles of 
therapy in patients without disease progression or limiting toxicity. 
Eligibility stipulated advanced NSCLC (Stage IV, “wet” and IIIB or 
recurrence after prior surgery/radiation); ECOG performance status 
0-1; measurable tumor, and adequate physiologic indices. 
Results: 53 patients were accrued at FCCC and its OPN partners 
Amongst the ﬁrst 32 patients enrolled, 53% were male; median age 
was 63 years (range 41-86), 47% were PS-0; 6% had received prior RT. 
Overall response rate was 55% (16/29) including one CR; 3 patients 
were not evaluable for response: one was found to have brain mets 
during week 1 and two experienced immediate HSRs. With median po-
tential F/U of ≥ 1 yr, median event-free survival was 5.3 months (n=30) 
and median survival 11.1 months (n=32). 25% (8/32), received 6 cycles 
of chemotherapy with 19% (6/32) going onto maintenance C225. Chief 
grade ≥ 3 attributable adverse events included neutropenia (28%); 
anemia (6%); HSR (9%) acneiform rash (28%) and hypomagnesemia 
(19%). Overall inc. (any grade) of rash was 84% and hypomagnesemia 
47%. Other signiﬁcant toxicities included grade 1-2 paronychia, with 
nail lysis and digital ﬁssures (19%), which tended to be cumulative. 
Conclusions: C225 in combination with monthly Cb and weekly Pac is 
highly active in advanced NSCLC. Response and survival data to date 
are promising. Toxicities match those seen with this PacCb alone, but 
also include persistent hypomagnesemia, and cumulative paronychia 
and nail changes, the latter troublesome, if not treatment-limiting. We 
will report the full results in 9/07.
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Background: CP-751,871 is a fully human, IgG2 monoclonal antibody 
against the Insulin Growth Factor I Receptor (IGF-IR) active in preclin-
ical models of NSCLC. We report the results of an ongoing phase Ib/II 
study in ten centers evaluating the safety and efﬁcacy of the combina-
tion of paclitaxel (T), carboplatin (C) and CP-751,871 (I) in advanced 
NSCLC. 
Methods: Phase Ib was an open-label dose-escalation study of T (200 
mg/m2), C (AUC of 6) and CP-751,871 (0.05-10 mg/kg) every 3 weeks 
for up to 6 cycles in patients with advanced solid malignancies; pts 
with response or stable disease could receive extended CP-751,871 
therapy. The ongoing phase II is an open label, randomized (2:1), 
non-comparative study of TCI versus TC alone. Only treatment-naïve 
NSCLC pts (stage IIIB or IV) are eligible in phase II. The statistical 
hypotheses are 28% (null) versus 40% - response of interest (RR) - for 
TCI. 
Results: Following informed consent and screening, 7 cohorts with a 
total of 30 pts, including 23 NSCLC pts, were enrolled in phase 1b. No 
dose limiting toxicities were identiﬁed and the recommended phase 2 
dose cohort of 10 mg/kg was extended to 12 pts. One case of isolated 
grade 3 GGT elevation attributed to CP-751,871 was reported. An in-
terim analysis for futility has been conducted at 73 pts enrolled in phase 
II: 48 treated with TCI; 25 with TC. TCI was well tolerated. All causal-
ity grade 3, 4 toxicity included (TCI, TC): hyperglycemia (20%, 10%), 
fatigue (15%, 8%), neutropenia (13%, 20%) and neuropathy (10%, 
4%).Twenty-two pts receiving TCI (46%) and 8 pts on TC alone (32%) 
had objective responses. Furthermore, 14 out of 27 TCI pts (52%) with 
non-adenocarcinoma responded to treatment. In addition, a PR was 
observed in 1 out of 4 TC pts who elected to receive single agent I after 
progression on TC alone. 
Conclusions: CP-751,871 appears safe in combination with TC. In-
terim TCI activity has warranted further investigation. An additional 83 
pts will be enrolled in phase II to assess further the safety and efﬁcacy 
of this treatment combination in NSCLC.
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Background: Vandetanib (ZACTIMA™; ZD6474) is a once-daily, oral 
anticancer drug that selectively inhibits vascular endothelial growth 
factor (VEGF), epidermal growth factor (EGF) and RET (REarranged 
during Transfection) receptor tyrosine kinase activity. Vandetanib was 
evaluated as a monotherapy in a randomized, double-blind, dose-ﬁnd-
ing study in Japan.
Methods: Eligible patients had locally advanced or metastatic (stage 
IIIB/IV) or recurrent NSCLC, after failure of one or two platinum-
based chemotherapy regimens. Patients were randomized to receive 
once-daily oral vandetanib 100, 200 or 300 mg (1:1:1), with stratiﬁca-
tion according to sex, histology (adenocarcinoma vs other histology) 
and smoking status (smoker vs non-smoker). Tumor response was 
assessed by RECIST every 4 weeks for the ﬁrst 24 weeks of treatment 
and then every 8 weeks until progressive disease (PD) or any other 
withdrawal criteria was met. The primary objective was to determine 
the objective response rate (ORR) for each vandetanib dose. Secondary 
assessments included disease control rate (DCR), safety and toler-
ability. Exploratory assessments included analysis of tumor samples 
for ampliﬁcation of EGFR gene copy number (ﬂuorescence in situ 
hybridization [FISH]) and somatic mutations of the EGFR gene, and 
measurement of plasma VEGF levels.
Results: Fifty-three patients (34 males/19 females, median age 60 
years, range 30–78) received vandetanib (100 mg, n=17; 200 mg, n=18; 
300 mg, n=18). The overall ORR was 13.2% (7/53; all partial responses 
[PRs]). The ORR in the vandetanib 100, 200 and 300 mg/day arms 
were 17.6% (3/17), 5.6% (1/18) and 16.7% (3/18), respectively. There 
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was no observed trend in patient characteristics for the PRs except 
that all had adenocarcinoma histology. The DCR (PR or stable disease 
[SD] ≥8 weeks) in the vandetanib 100, 200 and 300 mg/day arms were 
47.1%, 38.9% and 61.1%, respectively. The adverse event (AE) proﬁle 
was consistent with that observed in previous studies of vandetanib 
in NSCLC; the most common AEs were rash (53%), diarrhea (51%), 
hypertension (47%) and asymptomatic QTc prolongation (40%). There 
was one fatal case of interstitial lung disease, which was reported 8 
days after vandetanib 300 mg was discontinued because of PD. EGFR 
gene ampliﬁcation analysis revealed 4/12 patients were FISH positive 
(SD and PD, both n=2) and 8/12 were FISH negative (PR, n=1; SD, 
n=3; and PD, n=4). Tumors from 27 patients were evaluated for EGFR 
mutations: conﬁrmed mutation (n=1; exon 19 deletion [746–750]); con-
ﬁrmed no mutation (n=21); unconﬁrmed (n=5). The mutation-positive 
patient was a female non-smoker with FISH-positive adenocarcinoma 
and a best response of PD. Among the three PRs evaluated, two had no 
EGFR mutation and one had an unconﬁrmed result. Although patient 
numbers are small, baseline plasma VEGF levels (mean ± SE) appeared 
to be lower in patients who experienced clinical beneﬁt following van-
detanib treatment: PR (68.3 ± 40.4 pg/mL, n=6) and SD (50.5 ± 13.3 
pg/mL, n=16) versus PD (128 ± 39.5 pg/mL, n=23).
Conclusions: In Japanese patients with refractory NSCLC, vandetanib 
monotherapy (100–300 mg/day) demonstrated antitumor activity with 
an acceptable safety and tolerability proﬁle. The possible relationship 
between plasma VEGF levels and clinical outcome requires further 
investigation. 
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Background: Bevacizumab (Bv) in combination with carboplatin/pacl-
itaxel received FDA approval in October 2006 for improving response 
rates and survival in ﬁrst-line treatment of advanced NSCLC patients 
without brain metastases. Brain metastases were excluded based on 
a grade 3 intracerebral hemorrhage from a hepatocellular carcinoma 
brain metastasis in the original phase I study. Since NSCLC is the most 
common cause of brain metastases, a large fraction of patients who 
might beneﬁt from Bv have never been evaluated formally. We report 
here on the safety of Bv therapy in 24 subjects with NSCLC following 
local therapy for brain metastases.
Methods: Subjects were treated on protocols AVF3671g (ATLAS) or 
AVF3752g (PASSPORT): 
The ATLAS phase III study includes platinum based chemotherapy 
with Bv, followed by Bv ± erlotinib (E) to disease progression, for 
subjects with advanced or metastatic non-squamous NSCLC. Brain 
metastases subjects had to have completed whole brain radiotherapy 
(WBRT). 
The PASSPORT phase II study includes Bv combined with ﬁrst-line or 
second-line systemic therapy in subjects with non-squamous NSCLC 
with treated brain metastases. Treatment for Brain metastases included 
radiosurgery, neurosurgery or WBRT.
Demographic characteristics, baseline disease characteristics, prior 
treatment, and on-study treatment are summarized by study. The overall 
rate of CNS hemorrhage and exact 95% conﬁdence interval using the 
method of Blyth-Still-Casella are reported. 
Results: These results pertain to data collected on subjects enrolled 
from March 2006 to follow-up through January 2007.
STUDY ATLAS - AVF3671g PASSPORT - AVF3752g
N Total: 7 Total: 19
 Men: 5 Men: 12
 Women: 2 Women: 7
Median Age 60 64
ECOG Status ECOG 0: 4 ECOG 0: 7
 ECOG 1: 3 ECOG 1: 12
Prior Therapy for WBRT: 7 WBRT alone: 12
CNS Mets  WBRT w/Radiosurgery or
  Neurosurgery: 3
  Radiosurgery alone: 4
Treatment Line 1st Line: 7 1st Line: 9
  2nd Line: 10
Concomitant Med. for CNS Mets N/A 4 subjects
 
The mean number of Bv doses (15 mg/kg/q3w) in the 24 treated sub-
jects was 4 and the median was 3 (range 1-15). 2 subjects were never 
treated with Bv. 
There were no CNS hemorrhages reported on either study (95 % upper 
conﬁdence limit: 12.6%).
On ATLAS, no subjects experienced Grade 3/4 CNS events. One on-
study death due to disease progression occurred while the subject was 
on the study treatment follow-up period.
On PASSPORT, 2 subjects experienced new onset Grade 3 CNS events 
of seizures. One of these 2 subjects was not treated with Bv; the other 
had residual resolving hemorrhage at baseline prior to study treatment. 
Conclusions: These preliminary data are encouraging with respect 
to safe administration of bevacizumab to subjects with treated brain 
metastases in these two ongoing studies. It is anticipated that data on 40 
subjects will be available at presentation; additional follow-up and sub-
jects are necessary to more precisely characterize the CNS hemorrhage 
rate and overall safety of Bv treatment in this setting. 
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Vandetanib (ZACTIMA™; ZD6474) is a once-daily oral anticancer 
drug in Phase III clinical development in a broad population of patients 
